Off-Label Use of Atypical AntipsychoticsCause for Concern?

被引：0
|
作者：
Andrew McKean
Erik Monasterio
机构：
[1] The Princess Margaret Hospital,Pharmacy Department
[2] Hillmorton Hospital,Medlicott Academic Unit
来源：
CNS Drugs | 2012年 / 26卷
关键词：
Major Depressive Disorder; Anxiety Disorder; Risperidone; Olanzapine; Quetiapine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Licensed indications for medicines were designed to regulate the claims that can be made about a medicine by a pharmaceutical company. Off-label prescribing (i.e. prescribing a drug for an indication outside of that for which it is licensed) is legal and an integral part of medical practice. In psychiatry, off-label prescribing is common and gives clinicians scope to treat patients who are refractory to standard therapy or where there is no licensed medication for an indication. However, efficacy or safety of such off-label use may not be established.
引用
收藏
页码：383 / 390
页数：7
相关论文
共 50 条
  • [1] Off-Label Use of Atypical Antipsychotics Cause for Concern?
    McKean, Andrew
    Monasterio, Erik
    CNS DRUGS, 2012, 26 (05) : 383 - 390
  • [2] Rising off-label use of antipsychotics a concern in the US
    Reactions Weekly, 2011, 1336 (1) : 4 - 4
  • [3] Off-label use of atypical antipsychotics in personality disorders
    Rosenbluth, Michael
    Sinyor, Mark
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (11) : 1575 - 1585
  • [4] Off-label atypical antipsychotic use could be deadly
    Reactions Weekly, 2005, 1047 (1) : 3 - 3
  • [5] Off-label Atypical Antipsychotics
    不详
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 308 (12): : 1198 - 1198
  • [6] Off-label use of antipsychotics: Rethinking "off-label"
    Groleger, Urban
    PSYCHIATRIA DANUBINA, 2007, 19 (04) : 350 - 353
  • [7] Off-label use of atypical antipsychotics- Where are we?
    Vaz, R. P.
    Martins, J.
    Costa, A. L.
    Bras, J.
    Sousa, R.
    Almeida, E.
    Abreu, J.
    Castro, N.
    Andrade, R.
    Gil, N.
    EUROPEAN PSYCHIATRY, 2023, 66 : S305 - S305
  • [8] OFF-LABEL USE OF ATYPICAL ANTIPSYCHOTICS AT THE CRISIS INTERVENTION UNIT
    Sarotar, B. Novak
    Segrec, N.
    Pregelj, P.
    EUROPEAN PSYCHIATRY, 2009, 24
  • [9] Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?
    Peckham, Alyssa M.
    Evoy, Kirk E.
    Ochs, Leslie
    Covvey, Jordan R.
    SUBSTANCE ABUSE-RESEARCH AND TREATMENT, 2018, 12
  • [10] Off-label use of quetiapine in New Zealand-a cause for concern?
    Glue, Paul
    Gale, Chris
    NEW ZEALAND MEDICAL JOURNAL, 2011, 124 (1336) : 10 - 13
12345